KYOTO, Japan & LVIV, Ukraine — October 2026 — COGNANO, Inc. (Headquarters: Kyoto, Japan; President and CEO: Akihiro Imura; "COGNANO"), a biotechnology company pioneering high-resolution VHH antibody big data and AI-driven target discovery, has entered into a Memorandum of Understanding (MoU) with N-iX (Headquarters: Lviv, Ukraine / Florida, USA; "N-iX"), a global software solutions and engineering services company known for Pragmatic AI Software Engineering.

The agreement, executed at N-iX’s European engineering hub in Lviv, was facilitated with the support of the Japanese Services Group (JSG) at Deloitte Poland.

Through this strategic partnership, COGNANO will deploy its proprietary VHH antibody datasets and drug discovery algorithms at scale on top of an enterprise-grade AI and data engineering foundation engineered by N-iX.

Background

Over the past 15 years, COGNANO has conducted extensive research on single-domain antibodies (VHH antibodies) derived from camelids, such as alpacas. Today, the company possesses one of the world's most comprehensive biological repositories, covering more than 50 antigen classes with over 300 million gene sequence reads and 30 million labeled functional sequences.

Through its proprietary IBMET (Inverse Biomarker Exploring Technology) framework, COGNANO couples statistical mathematics with Large Language Models (LLMs) to identify disease-specific conformational epitopes and uncover novel therapeutic targets and biomarkers directly from immune repertoires.

However, as the volume and structural complexity of biological data continue to expand exponentially, realizing the platform’s full translational potential demands enterprise-grade data platforms and production-proven AI engineering capable of rapidly and reliably processing hundreds of millions of biological data points under high computational workloads.

To meet these requirements and scale its global data infrastructure, COGNANO has selected N-iX—a global technology partner backed by more than 2,400 top-tier engineers across Europe, the Americas, and APAC, with over two decades of experience supporting production systems for Fortune 500 enterprises.

About N-iX

N-iX is a global technology company championing Pragmatic AI Software Engineering—the practice of delivering measurable, proven value on actual codebases and in real-world production environments.

• Top-Tier Cloud & AI Credentials: AWS Premier Tier Services Partner holding the AWS AI Services Competency, with established partner ecosystems across major enterprise platforms including Microsoft Azure, Google Cloud, Palantir, Snowflake, and SAP.
• Large-Scale Data Engineering: Proven track record in designing petabyte-scale data lakes and high-throughput pipelines for highly regulated industries requiring strict data governance and ultra-fast processing, including healthcare, life sciences, finance, and supply chain.
• Specialized LLM & MLOps Infrastructure: Deep domain expertise in high-performance distributed computing and MLOps/LLMOps operations, specializing in fine-tuning complex domain-specific models and establishing scalable inference architectures.

Key Initiatives Under the Partnership

Under this agreement, COGNANO will work closely with N-iX’s engineering team to advance the following initiatives:

• Optimizing Data Platform Infrastructure: Engineering scalable, high-throughput pipelines to securely ingest, process, and store over 300 million sequence reads alongside complex 3D structural data.
• Establishing High-Performance Compute Environments: Deploying specialized computational architectures to decode and translate the bidirectional relationships between antibody sequence diversity and disease-specific epitopes with high fidelity.
• Accelerating the IBMET Pipeline: Operationalizing IBMET across the expanded infrastructure to significantly shorten the discovery lifecycle of selective antibody therapeutics and next-generation diagnostic candidates for intractable diseases such as cancer.
• Enhancing Global Data Interoperability: Improving data accessibility to power international open science initiatives like SEPIQ and facilitate co-development partnerships with global pharmaceutical companies and research institutions.

Company Profiles